CURR - CURE Pharmaceutical Holding Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
1.3800
-0.0300 (-2.13%)
At close: 3:56PM EST
Stock chart is not supported by your current browser
Previous Close1.4100
Open0.0000
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.0000 - 0.0000
52 Week Range
Volume0
Avg. Volume54,993
Market Cap35.833M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.42
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire14 days ago

    CURE Pharmaceutical Secures U.S. DEA Approval to Manufacture Cannabinoid-based Pharmaceuticals

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it has secured a new registration with the Drug Enforcement Administration (DEA) as a manufacturer authorized to handle Schedule 1 controlled substances. With this license, CURE will develop and manufacture cannabinoid-based pharmaceutical products using its CUREfilm™ technology at its facility in Oxnard, Calif. “This license enables CURE to translate the research findings from our collaboration with Technion – Israel Institute of Technology into potential treatments and expand our marketable product lines,” said Jessica Rousset, Chief Operating Officer of CURE Pharmaceutical.

  • GlobeNewswire26 days ago

    CURE Pharmaceutical Names Veteran Executive as Chief Financial Officer

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it has tapped Alex Katz to be the company’s Chief Financial Officer. Bringing his expertise in venture capital, Katz will oversee the company’s financial functions and investment relations. “Our company is approaching 2019 amidst exponential growth and a clear vision to be a leader in drug delivery innovation,” said Robert Davidson, CEO and Chairman of the Board of CURE Pharmaceutical.

  • GlobeNewswirelast month

    Prominent Biotech Investor Gene Salkind Adds Another $2M Investment in CURE Pharmaceutical

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, has announced that the company secured a $2 million investment at $2.5 per share from Gene Salkind, a company advisor and biotech investor, bringing his total investment in the company to $3 million. In February 2018, Dr. Salkind joined CURE’s advisory board to help advance CURE’s pipeline for the central nervous system and other therapeutic areas. “This second round of financing from Dr. Salkind is an example of the confidence our investors see in the company’s future,” said Robert Davidson, CEO and Chairman of the Board of CURE Pharmaceutical.

  • GlobeNewswire2 months ago

    CURE Pharmaceutical to Present at CannX 2018 International Medical Cannabis Conference

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, will be presenting at this year's CannX Conference on October 15 at 11:15 AM in Tel Aviv, Israel. CURE Pharmaceutical CEO Rob Davidson will present on “Maximizing and Understanding the Benefits of Proprietary Delivery Technologies for Increasing Bioavailability of Cannabinoid Molecules” and will be meeting with investors.

  • GlobeNewswire2 months ago

    CURE Pharmaceutical to Present at The MicroCap Conference on October 1st and 2nd in New York City at the Essex House

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, will be presenting at this year's MicroCap Conference on October 1st at 2:30 PM in New York City. CURE Pharmaceutical CEO Rob Davidson will be discussing the latest innovations and partnerships from CURE and meeting with investors. The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks.

  • GlobeNewswire2 months ago

    CURE Pharmaceutical Secures Patent for Oral Thin Film Containing Bioactive Cannabinoid Molecules

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, announced the allowance of an oral thin film patent (U.S. Patent No. 10092611), which covers the processing and integration of bioactive cannabinoid molecules into oral thin film dosage forms, such as CUREfilm™, the most advanced oral thin film on the market today. “With over 140 cannabinoid molecules present in the cannabis plant, we have only seen a glimpse of the potential of cannabinoids to treat many diseases and illnesses,” said Rob Davidson, CEO and Chairman of CURE Pharmaceutical.

  • Business Wire10 months ago

    CURE Pharmaceutical Adds New VP of Strategy and Business Development

    CURE Pharmaceutical , an innovative drug delivery and development company, today named Dr. Vered Gigi, Vice President of Strategy and Business Development. Dr.